Abstracts tagged "Joint Structure"

Abstract Number: 2207 • ACR Convergence 2022
Structural Ultrasound Features of Joints and Tendons of Healthy Children: Development of Normative Data
Ruth Wittoek¹, Céline Decock², Nele Dewaele², Lara Arnold³, Pieter baeyens⁴, Ignace Deschrijver⁴, Lisa Pardaens⁵, Ioannis Raftakis⁶, Thomas Renson⁷, Alexander D.J. Thooft⁸, Charline Rinkin⁹, Tine Vanhaverbeke⁵ and Caroline Verbist¹⁰, ¹Dept. of Rheumatology, Ghent University Hospital, Ghent University, Gent, Belgium, ²Ghent University, Faculty of Medicine, Ghent, Belgium, ³Dept. Of Rheumatology, Maastricht UMC+, Maastricht, Netherlands, ⁴Dept. of Radiology, Clinique de Flandre, Coudekerque-Branche, France, ⁵Ghent University, Faculty of Internal Medicine and Pediatrics, Gent, Belgium, ⁶Dept. of Rheumatology, CHU-Brugmann Hospital Brussels, Brussels, Belgium, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Ghent University, Faculty of Internal Medicine and Pediatrics, Ghent, Belgium, ⁹Dept. of Rheumatology, CHU Liège, Liège, Belgium, ¹⁰Dept. of Rheumatology, AZ Delta, Roeselare, Belgium, Roeselare, Belgium
Background/Purpose: Ultrasound is a highly valuable imaging modality to study joints in patients with rheumatic diseases. In children, the applicability is hampered because of lack…
Abstract Number: 0267 • ACR Convergence 2022
Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
Juan Molina¹, Fernando Sanchez-Alonso², Cristina Bohorquez³, Cesar Diaz-Torne⁴, Carolina Perez-Garcia⁵, Juan Maria Blanco-Madrigal⁶, Paloma Vela-Casampere⁷, José María Älvaro-Gracia¹ and Isabel Castrejon⁸, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, ³University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, ⁴Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Department of Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To investigate the occurrence and relative risk of incident malignancy in patients with rheumatic diseases and previous malignancy treated with biologic and targeted synthetic…
Abstract Number: 0404 • ACR Convergence 2022
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
Raphael Micheroli¹, Tim Killeen², Hyejin Jo³, Kenneth Kwok³, Bassel Elzorkany⁴, Caroline Ospelt⁵, Adrian Ciurea⁶ and Michael Nissen⁷, ¹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ²Pfizer Ltd, Tadworth, Switzerland, ³Pfizer Inc, New York, NY, ⁴Department of Rheumatology, Cairo University, Cairo, Egypt, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland
Background/Purpose: Sites of peripheral joint and enthesitis involvement in AS vary. Tofacitinib is an oral Janus kinase inhibitor for the treatment of AS. Differential site-specific…
Abstract Number: 0504 • ACR Convergence 2022
Three-dimensional Ground Reaction Force Symmetry Metrics Largely Fail to Explain Cartilage Worsening in the Contralateral Knee in Persons with Unilateral Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Patrick Corrigan¹, Cara Lewis², Kerry Costello², Ali Guermazi², Frank Roemer³, Deepak Kumar², David Felson², Kathryn Bacon², Tuhina Neogi⁴, Michael LaValley⁵, Michael Nevitt⁶, Cora E. Lewis⁷, James Torner⁸ and Joshua Stefanik⁹, ¹Saint Louis University, St. Louis, MO, ²Boston University, Boston, MA, ³Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, ⁴Boston University School of Medicine, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA, ⁶University of California San Francisco, Orinda, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Iowa, Iowa City, IA, ⁹Northeastern University, Boston, MA
Background/Purpose: Knee osteoarthritis (KOA) often starts as a unilateral disease and commonly progresses to bilateral KOA. There is a need to identify mechanisms that explain…
Abstract Number: 0159 • ACR Convergence 2021
Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
Xenofon Baraliakos¹, Valeria Rios Rodriguez², Murat Torgutalp², Anil Dilbaryan², Hildrun Haibel³, Maryna Verba⁴, Joachim Sieper³, Jürgen Braun¹, Martin Rudwaleit⁵ and Denis Poddubnyy⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁵University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: The aim of this study is to investigate the performance of the modified Stokes Ankylosing Spondylitis Scoring System (mSASSS) in assessing spinal radiographic damage…
Abstract Number: 0737 • ACR Convergence 2021
Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
Sumir Brahmbhatt¹, Ahsan Iqbal¹, Fatemeh Farshami², Maheswari Muruganandam³, Jaren Trost⁴, David Cisneros⁵, Adnan Kiani³, N. Suzanne Emil³, Sharon Nunez¹, William Hayward⁶, Philip Band⁷ and Wilmer Sibbitt³, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, MD, ³University of New Mexico, Albuquerque, NM, ⁴Optum, Albuquerque, NM, ⁵University of New Mexico School of Medicine, Albuquerque, NM, ⁶New Mexico Highlands University, Las Vegas, NM, ⁷NYU SOM, New York, NY
Background/Purpose: To explore an alternative to standard extended knee arthrocentesis using pneumatic compression of the flexed knee.Methods: Using a paired sample design, 41 consecutive effusive…
Abstract Number: 0930 • ACR Convergence 2021
Effect of Tofacitinib on Spinal Vertebral Body and Posterolateral Element Inflammation and Structural Lesions Using the Canada-Denmark MRI Scoring System in Patients with Ankylosing Spondylitis: Results from a Phase 2 Study
Mikkel Ostergaard¹, Joseph Wu², Lara Fallon³, Sarah P Sherlock⁴, Cunshan Wang², Dona L Fleishaker², Keith S Kanik² and Walter Maksymowych⁵, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ²Pfizer Inc, Groton, CT, ³Pfizer Canada, Montréal, QC, Canada, ⁴Pfizer Inc, Cambridge, MA, ⁵Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: The Canada-Denmark (CANDEN) MRI scoring system enables detailed anatomy-based evaluation of inflammatory and structural lesions in spinal vertebral bodies and posterior elements in patients…
Abstract Number: 1051 • ACR Convergence 2021
Variance of Joint Space Width Across the Tibiofemoral Joint on Knee Radiographs: A Novel Measure of Structure and Progression
Kent Kwoh¹, Erin Ashbeck², Edward Bedrick¹, Xiaoxiao Sun¹ and Jeffrey Duryea³, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: The FDA accepts medial minimum joint space width (mJSW) in the tibiofemoral (TF) compartment as the standard for structural change in clinical trials of…
Abstract Number: 1349 • ACR Convergence 2021
Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study
Adrian Ciurea¹, Tim Killeen², Raphael Micheroli¹, Norina N Gassman², Hyejin Jo³, Kenneth Kwok⁴, Elizabeth Kudlacz⁴, Oliver Distler¹, Caroline Ospelt⁵ and Mojca Frank-Bertoncelj¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ²Pfizer AG, Zurich, Switzerland, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Peripheral joint involvement in PsA varies. In RA, varied joint involvement may reflect site-specific differences in stromal cell transcriptome, including Janus kinase-signal transducer and…
Abstract Number: 1778 • ACR Convergence 2021
The Role of Cathepsin G in Joint Destruction in Patients with Psoriatic Arthritis
Mariela Geneva-Popova¹, Stanislava Popova¹ and Anastas Batalov², ¹Medical University, Faculty of Medicine, Department of Propedeutic of Internal Diseases, Plovdiv, Bulgaria, ²UMHAT KASPELA, Plovdiv, Bulgaria
Background/Purpose: Cathepsin G (CTSG) is a member of the serine protease family. It is stored in primary granules of myeloid cells, dendritic cells, plasma cells,…
Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Désirée van der Heijde¹, Cynthia E Kartman², Li Xie², Scott Beattie², Douglas Schlichting², Patrick Durez³, Yoshiya Tanaka⁴ and Roy Fleischmann⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Eli Lilly and Company, Indianapolis, IN, ³Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…
Abstract Number: 1389 • ACR Convergence 2020
Clinical Characteristics and Treatment Outcome of a Cohort of Patients with Joint and Fascial Involvement in the Context of Chronic Graft versus Host Disease
Cristina Hidalgo Calleja¹, Concepción Román Curto², Luis Gómez-Lechón³, Maria Elisa Acosta², Olga Compán⁴, Sonia Pastor², Carlos Montilla Morales², Lucía Pantoja Zarza⁵, María Dolores Sánchez González⁶ and Lucía López Corral², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Francesc de Borga de Gandía, Valencia, Spain, ⁴Hospital Universitario de Salamanca, ´Salamanca, Spain, ⁵Complejo Asistencial Hospital General de Segovia, Segovia, Spain, ⁶Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Background/Purpose: Chronic graft-vs-host disease (cGVHD) is a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT), typically occurring within three years post-transplant and affecting…
Abstract Number: 1651 • ACR Convergence 2020
Efficacy and Safety of Multiple Intra-articular Corticosteroid Injections for Osteoarthritis – a Systematic Review and Meta-analysis of Randomised Controlled Trials and Observational Studies
Shazeen Ayub¹, Jaspreet Kaur¹, Michelle Hui², Michelle Hall¹, Michael Doherty³ and Weiya Zhang¹, ¹Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, United Kingdom, ²Royal Derby Hospital, Derby, UK, Derby, United Kingdom, ³Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, England, United Kingdom
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis worldwide and is becoming more prevalent with the increasing age of the population. As Intra-articular…
Abstract Number: 1663 • ACR Convergence 2020
Walking for Exercise May Be Symptom and Structure Modifying for Those with Established OA and with Varus Alignment – Data from the Osteoarthritis Initiative
Grace Lo¹, Surabhi Vinod², Matthew Harkey³, Timothy McAlindon⁴, Andrea Kriska⁵, Bonny Rockette-Wagner⁵, Charles Eaton⁶, Marc Hochberg⁷, Rebecca Jackson⁸, C. Kent Kwoh⁹, Michael Nevitt¹⁰ and Jeffrey Driban⁴, ¹Michael E. Debakey VA Medical Center, Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³University of Massachusetts, Worcester, MA, ⁴Tufts Medical Center, Boston, MA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Department of Family Medicine and Epidemiology, Warren Alpert Medical School of Brown University,Department of Epidemiology, School of Public Health of Brown University, Providence, RI, ⁷University of Maryland School of Medicine, Baltimore, MD, ⁸Ohio State University, Columbus, OH, ⁹The University of Arizona, Tucson, AZ, ¹⁰University of California, San Francisco, San Francisco, CA
Background/Purpose: Walking for exercise is recommended for knee osteoarthritis (OA) management though benefits have not been demonstrated in epidemiologic studies. We aimed to assess the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].